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Abstract
Serrated adenocarcinoma (SAC) is more invasive, has worse outcomes than conventional colorectal carcinoma (CRC),
and is characterized by frequent resistance to anti-epidermal growth factor receptor (EGFR) and overexpression of
fascin1, a key protein in actin bundling that plays a causative role in tumor invasion and is overexpressed in different
cancer types with poor prognosis. In silico screening of 9591 compounds, including 2037 approved by the Food and
Drug Administration (FDA), was performed, and selected compounds were analyzed for their fascin1 binding affinity
by differential scanning fluorescence. The results were compared with migrastatin as a typical fascin1 inhibitor. In silico
screening and differential scanning fluorescence yielded the FDA-approved antidepressant imipramine as the most
evident potential fascin1 blocker. Biophysical and different in vitro actin-bundling assays confirm this activity.
Subsequent assays investigating lamellipodia formation and migration and invasion of colorectal cancer cells in vitro
using 3D human tissue demonstrated anti-fascin1 and anti-invasive activities of imipramine. Furthermore, expression
profiling suggests the activity of imipramine on the actin cytoskeleton. Moreover, in vivo studies using a zebrafish
invasion model showed that imipramine is tolerated, its anti-invasive and antimetastatic activities are dose-dependent,
and it is associated with both constitutive and induced fascin1 expression. This is the first study that demonstrates an
antitumoral role of imipramine as a fascin1 inhibitor and constitutes a foundation for a molecular targeted therapy for
SAC and other fascin1-overexpressing tumors.
Introduction
Tumor metastasis is the leading cause of cancer-related
deaths1. Cell migration and invasion are fundamental
features of metastatic cancer cells and involve actin
cytoskeleton rearrangement, leading to the formation of
protrusive structures, such as filopodia, lamellipodia, and
invadopodia, that contribute to cancer cell motility2.
Fascin1 is an actin filament (F-actin) bundling protein
that plays an important role in the formation of protrusive
structures and is poorly expressed or absent in most
normal epithelia but upregulated in many human carci-
nomas, with a crucial role in tumor progression, invasion,
and metastasis3,4. Numerous studies have implicated fas-
cin1 as a potential therapeutic target and biomarker for
aggressive carcinomas4,5. Recently, our group identified
fascin1 as overexpressed in serrated adenocarcinoma
(SAC), a WHO-recognized histological subtype of color-
ectal carcinoma (CRC), which is characterized by worse
prognosis6 and a more active invasive front as evidenced
by a higher occurrence of tumor budding7, E-cadherin
loss, and more frequent KRAS or BRAF mutations com-
pared with conventional CRC8–10. Migrastatin and its
macroketone analogs have been found to efficiently
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inhibit fascin1, thus decreasing metastatic tumor cell
migration, invasion, and further metastasis1. However, the
complex structure of the macroketone hinders its synth-
esis, and other anti-fascin1 compounds derived from
indazol-furan-carboxamides have been tested11. To
identify novel molecules targeting fascin1 as potential
anti-SAC drugs, we performed an in silico compound
library screening and subsequent in vitro and in vivo
assays to characterize the anti-fascin1, antimigratory, and
anti-invasive potential of the selected compounds.
Materials and methods
In silico screening
In silico screening12 was applied to propose compounds
that might have better fascin1 inhibitory properties than
migrastatin. Pharmacophore modeling using LigandSc-
out13,14 was employed to the core of the structure of
migrastatin (MGS_CORE) so that a ligand-based phar-
macophore model15 was derived. This model was
screened against a subset of the DrugBank library (version
5.0; of 9591 compounds, including 2037 approved by the
American FDA, 96 nutraceuticals, and 6000 experimental)
after fine-tuning on a high-performance computing
(HPC) cluster of all related necessary programs from the
LS suite.
Thermofluor and fluorescence titration
Differential scanning fluorimetry (Thermofluor) and
titration assays were performed as described in Sup-
plementary Information S1. Briefly, the thermal dena-
turation profiles of fascin1 (cat. no. 8411-02,
Hypermol, Bielefeld, Germany) were obtained by
recording the fluorescence intensity for the FAM, HEX,
and T-Red predefined filters. Tm values were measured
as the minimum of the first derivative of the thermal
unfolding profile. Changes in Tm associated with ligand
binding were estimated, taking the average Tm value
derived from the free protein internal controls. Drugs
were provided by MolPort, Latvia (migrastatin, Ana-
lytiCon Discovery, cat. no. NP-006108, and imipra-
mine, Biotrend Chemicals, BG0219).
F-actin bundling assay
The actin-bundling activity in the presence of drugs was
measured by a low-speed centrifugation assay using the
Actin Binding Protein Biochem KitTM Muscle Actin
(Cytoskeleton, Inc., cat. no. BK001) and following the
manufacturer’s manual. Additional information is pro-
vided as Supplementary Information S1.
Transmission electron microscopy
Transmission electron microscopy (TEM) was assessed
following the methodology of a previous paper16. Protocol
details are provided as Supplementary Information S1.
Cell culture
A total of eight human colorectal adenocarcinoma cell
lines—SW-480 (CLS Cat# 300302/p716_SW-480, RRID:
CVCL_0546), DLD-1 (CLS Cat# 300220/p23208_DLD-1,
RRID: CVCL_0248), HCT-15 (CLS Cat# 300229/
p23303_HCT-15.html, RRID: CVCL_0292), HCT-116
(CLS Cat# 300195/p19841_HCT116.html, RRID:
CVCL_0291), HT-29 (NCI-DTP Cat# HT-29, RRID:
CVCL_0320), LS174T (CLS Cat# 300392/p720_LS-174T,
RRID: CVCL_1384), SW-620 SW620 (NCI-DTP Cat#
SW-620, RRID: CVCL_0547) and LoVo (NCI-DTP Cat#
LOVO, RRID: CVCL_0399)—were obtained from the
American Type Culture Collection (ATCC, Rockville,
Maryland). The cell lines were cultivated at 37 °C in high-
glucose Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% heat-inactivated fetal bovine serum (FBS),
50 U/mL penicillin, and 50 µg/mL streptomycin (Sigma-
Aldrich Chemical Co., USA) in an atmosphere of 5% CO2
and 95% humidified air. Subculture was performed when
90% confluence was reached. Human cell line identifica-
tion by short tandem repeat profile testing, according to
the American National Standards Institute, has shown an
appropriate match for HCT-116 and DLD-1 cell lines.
Quantification PCR for fascin1 mRNA expression
Fascin1 gene expression was measured following the
protocol previously described2. The relative quantitation
was obtained by the 2-ΔCt method using β-actin as the
housekeeping gene. The amounts of mRNA are given as
the number of copies per million copies of β-actin. Pri-
mers for β-actin used for FSCN quantitation are shown in
Supplementary Information S1.
Cell viability assay
Exponentially growing cells were plated in triplicate in flat-
bottomed 96-well plates (Nunc, Roskilde, Denmark) at 1500
cells/well. On the day after plating, drugs were added in serial
dilutions from 500 nm to 300 µM. Control wells contained
medium without drug plus 0.1% dimethyl sulfoxide (DMSO)
(drug carrier). The plates were incubated for 3 days in a
humidified 5% CO2 incubator and assayed for cell viability.
Tetrazolium, dissolved in phosphate-buffered saline, pH 7.2,
at 1.9mg/mL was added to the cells (30 µL/well). Additional
information is provided as Supplementary Information S1.
RNA labeling, microarray hybridization, and functional
enrichment analysis
To obtain a general overview of enriched functions
associated with the treatment of colorectal cancer tumor
cells, HCT-116 cells were treated with DMSO or imi-
pramine. Detailed information is included in Supple-
mentary Information S1. Datasets are deposited in the
Gene Expression Omnibus database under accession
number GSE125169.
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Immunofluorescence
For the immunofluorescence assays, round coverslips
(Thermo Fisher, Waltham, Massachusetts) were seeded with
HCT-116 cells in the presence of 10% FBS. Artificial
wounding was performed by transversally dragging a ster-
ilized razor blade on the central area of the coverslips. Briefly,
cancer cells were treated with 100 µM migrastatin, 20 µM
imipramine, 10 ng/mL epidermal growth factor (EGF), or
50 μM MEK inhibitor PD98059 (MEKi) (both from Sigma-
Aldrich, St. Louis, Missouri, USA) for 24 h. Additional
information is shown as Supplementary Information S1.
Cell migration assay
Cell migration was executed with SW-480, DLD-1, and
HCT-116 cell lines by performing the wound-healing assay
in the presence of 10% FBS. Colorectal cancer cells (50,000
cells) were plated in low 35-mm dishes with culture inserts
(Ibidi, Martinsried, Germany). After appropriate cell
attachment and monolayer formation (approximately
24 h), inserts were then removed with sterile forceps to
create a wound field of approximately 500 µm, according
to the manufacturer’s protocol. Additional information is
shown in Supplementary Information S1.
Transwell invasion assay
The invasive capacities of HCT-116 cells were deter-
mined using a Cell Biolabs CytoselectTM 24 Well Cell
Invasion Assay Kit (Basement Membrane Colorimetric
Format, Cat: CBA-110, Cell Biolabs, CliniScience, Barce-
lona, Spain) with coated transwell chambers (8 μm pore
size) following the instruction manual. Cells were resus-
pended in serum-free medium and treated under the
corresponding conditions (0.1% DMSO, 100 µM migras-
tatin, and 20 µM imipramine). Additional information is
shown in Supplementary Information S1.
Myoma organotypic invasion model
Cancer cell invasion was assessed in the myoma organo-
typic cultures and performed according to the previously
published myoma model protocol17,18. Briefly, uterine leio-
myoma tissues were obtained from routine surgery after
informed consent of the donors. Myoma (8mm disks) were
preincubated with migrastatin (100 μM), imipramine (10 µM
and 20 µM), or 0.1% DMSO-DMEM treatments at 4 °C for
48 h and placed into transwell inserts (6.5mm diameter;
Corning Incorporated, Corning, New York), and 700,000
cells were added on top of each myoma disk. The cells were
allowed to attach overnight on the myoma disks, transferred
onto uncoated nylon disks, and treated with the compounds
for 14 days. After fixation, 6-μm sections were cut and
stained with cytokeratin AE1/AE3 (M3515, Dako). ImageJ
v1.46o was used to measure invasion areas and depths. Each
treatment was performed in triplicate. Additional informa-
tion is shown in Supplementary Information S1.
Transfection assay
The day before transfection, DLD-1 cells were seeded in
six-well plates and then cultured overnight. The trans-
fection efficiency of lipofectamine 2000-based liposomes
was determined using the GFP reporter gene. The pGFP-
N3 control vector (MOCK) and fascin1-GFP vector were
kindly provided by Dr. Milind Vaidya from the Advanced
Centre for Treatment Research and Education in Cancer
(Maharashtra, India). The final amount of DNA plasmids
was 1 µg/well. Details regarding this experiment are pro-
vided as Supplementary Information S1.
Zebrafish invasion and metastasis assays
The colonization of zebrafish (Danio rerio) embryos by
human cancer cells was performed as previously described19.
Trypsinized, washed colorectal cancer cells were stained with
fluorescent CM-Dil (Vybrant, Invitrogen), and 50–100
labeled cells were injected into the yolk sac of dechorionated
zebrafish embryos. The viability of zebrafish embryos was
assessed under 100 μMmigrastatin or imipramine (5, 10, and
20 µM) treatments and under the combined effect of com-
pound treatment and tumor cell injection. The evaluation
criterion for embryos being colonized by human cancer cells
was the presence of more than three cells outside the yolk
sac. The metastasis assay was based on previous works by
Fior et al.20, and a metastatic potential assay on zebrafish was
performed. Transfected DLD-1-overexpressing fascin1 and
native HCT-116 cells were stained and xenografted as
already mentioned. From the third day post injection, larvae
were fed with ZEBRAFEED by Sparos (<100 µm) and treated
with imipramine daily. At day 6 post injection, larvae were
examined for monitoring of tumor growth and invasion
using a fluorescence microscope. The evaluation for metas-
tasis potential by human cancer cells was the presence of cell
colonies (dividing cells) outside the yolk sac. Fishes with
fluorescently labeled cells appearing outside the implantation
area at 2 h post injection were excluded from further analysis.
All the fish were incubated at 35 °C and analyzed with a
SteReo Lumar V12 stereomicroscope equipped with an
AxioCam MR5 camera (Carl Zeiss). The percentage of
invasion and the presence of cell colonies were calculated by
the researcher (M.B.-G.) without previous knowledge of the
experimental treatment conditions. The experiments were
completed in triplicate, obtaining an average value at 4 days
post xenograft (invasion assay) and 6 days post xenograft
(metastasis assay).
Chemical treatment
The effect of treatments on the zebrafish invasion
model was tested in two ways: one treating cancer cells
before injection in the larvae, and the other treating the
larvae with the drugs once injected with tumor cells.
Additional information is shown in Supplementary
Information S1.
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Statistics
Data are expressed as the mean ± standard deviation
(SD). The data were analyzed for significant differences by
Student’s t test for paired and unpaired data after testing
for normal distribution of the data. For in vitro experi-
ments, one-way analysis of variance (ANOVA) was per-
formed, followed by a Tukey post hoc test to compare
each group. Differences were considered significant at an
error probability of p < 0.05. SPSS 18.0 software was used
for the rest of the statistical analyses (SPSS, Inc., Chicago,
Illinois, USA).
Ethics statement
For the myoma organotypic invasion model, uterine
leiomyoma tissues were obtained from routine surgery
after informed consent of the donors and their use
approved by the Ethics Committee of the Oulu University
Hospital, Oulu, Finland, in accordance with the ethical
standards laid down in the 1964 Declaration of Helsinki
and later amendments. The studies on zebrafish were
approved by the Bioethical Committee of the University
Hospital Virgen de la Arrixaca, Murcia, Spain.
Results
In silico screening identifies imipramine as a plausible
ligand for fascin1
In silico screening calculations and careful visual
inspection of the results1,21 detected imipramine as one of
the top 31 candidates for posterior experimental valida-
tion. The pharmacophore model derived for imipramine
is depicted in Fig. 1.
Thermofluor and fluorescence titration experiments
validate imipramine binding to fascin1 in vitro
The binding capacity of the distinct compounds to
fascin1 was tested using differential scanning fluori-
metry. As shown in Supplementary Information S2, at
pH 7.4, fascin1 unfolds in a single transition, showing
no concentration dependency (panel A) and good tol-
erance to DMSO (panel B). Average Tm values for
unbound fascin1 were obtained for each internal filter
(FAM, HEX, and T-Red) as reference for the determi-
nation of the changes in Tm upon compound binding
(Tm,FAM= 55.6 ± 0.5 °C, Tm,HEX= 56.0 ± 0.0 °C, Tm,Tred
= 56.2 ± 0.6 °C, where the error values correspond to
the SD for the seven replicas included in each plate as
internal controls). The results of the thermal shift assay
with the top 31 compounds are summarized in Sup-
plementary Information S1 (Table S1) and shown in
Fig. 2a. Some compounds resulted in distorted thermal
unfolding profiles from which reliable Tm values could
not be extracted, probably due to compound inter-
ference with the SYPRO fluorescence signal. Within
those that could be analyzed, imipramine resulted in
the highest significant increase in Tm of approximately
2 °C, suggesting specific binding to fascin1 (Fig. 2a,
arrow). The binding of imipramine to fascin1 was
further validated in vitro using fluorescence titration
experiments, rendering a dissociation constant of
390 μM (Fig. 2b).
Imipramine significantly decreases the fascin1-induced
bundles
In the absence of fascin1, although the bundles of
F-actin polymers are present in the pellets, the majority of
F-actin was observed in the supernatant fraction. As
shown in Fig. 3, purified fascin1 increased the amount of
F-actin localized in the pellets. However, upon imipra-
mine addition, the F-actin pellet fraction significantly
diminished in favor of the supernatant. Taken together,
these results indicate that imipramine partially interferes
with fascin1 in bundling F-actin polymers.
Electron microscopy confirms imipramine-driven alteration
of actin bundling
Transmission electron microscopy showed that only
polymerized F-actin incubated in the presence of fascin1
was able to form filament bundles (9.00 [8.00–9.75])
(Fig. 4). Fascin1 preincubated with 100 μM migrastatin or
10 μM imipramine led to the disorganization of the
bundles, resulting in fewer filaments than in control
conditions (Kruskal–Wallis test, p < 0.001). No significant
differences were found between the distinct treatments
(Mann–Whitney test, p= 0.370).
The expression of fascin1 mRNA varies among different
colorectal cell lines
To choose colorectal cell lines with the highest and lowest
endogenous fascin1 expression, RT-qPCR was performed
on RNA extracted from the eight colorectal cancer cell
lines. Supplementary Information S3 illustrates how
Fig. 1 Results obtained after ligand-based pharmacophore
screening with LigandScout. a 2D diagram of matching hydrophobic
pharmacophoric features between (yellow spheres) migrastatin and
imipramine. b 3D alignment of migrastatin (blue skeleton) and
imipramine (yellow skeleton).
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HCT-116 and SW-480 cells show the highest fascin1
expression, while LoVo, DLD-1, and HT-29 cells show the
lowest expression. Given the ease of cell culture and the
suitable morphology with prominent cytoplasm for immu-
nofluorescence, migration, and invasion assessment, DLD-
1, SW-480, and HCT-116 cell lines were selected for sub-
sequent in vitro assays.
High imipramine concentrations compromise cancer cell
viability
Compounds might be toxic to cancer cells, and the
effects observed could be a consequence of a general effect
of cell functionality and not a specific drug effect. For this
purpose, a viability assay on DLD-1, HCT-116, and SW-
480 cells was performed to set up the working con-
centration of the drugs. According to data presented as
Supplementary Information S4, HCT-116 was more sen-
sitive than DLD-1 and SW-480, and the working
concentrations were set up for subsequent in vitro studies
at 10 and 20 µM imipramine and 100 µM migrastatin.
Identification of imipramine-associated enriched functions
To determine which general functions are affected
upon imipramine treatment, expression profiling of
imipramine-treated HCT-116 colorectal cancer cells
from a migration assay was undertaken. Functional
enrichment analysis revealed a large number of differ-
entially expressed genes compared with the control
treatment (DMSO), among which we selected the top
2000 genes. The Panther Classification System Program
was used, and as shown in Supplementary Information
S5, 18 Gene Ontology molecular functions were related
to these genes. Interestingly, actin binding (GO:
0003779), cytoskeletal protein binding (GO: 0008092),
and structural constituent of cytoskeleton (GO:
0005200) were among these 18 functions.
Fig. 2 In vitro validation of imipramine binding to fascin1. a Differential scanning fluorimetry assays. The right panel shows the first derivative of
the thermal denaturation profiles of fascin1 in the absence (black) and in the presence of 1 mM imipramine (red in triplicate). The left panel
summarizes the changes in Tm induced by the presence of the selected compounds at 1 mM in 10% DMSO. b Fluorescence titration. The right panel
shows the fluorescence emission spectra of fascin1 in the presence of increasing concentrations of imipramine. The left panel shows the binding
isotherm. White circles represent the center of mass of the different spectra, and the continuous lines symbolize the best fit of the data to a one-site
binding model.
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Imipramine affects fascin1 localization and lamellipodium
formation
The effect of imipramine on fascin1 localization and
actin reorganization, including lamellipodium forma-
tion, was assessed by immunofluorescence. Figure 5
shows the fascin1 localization (green) in two cell lines,
the cell line expressing higher fascin1 level, HCT-116,
and a nontumoral cell line derived from keratinocyte
cells, HaCaT, which was used for illustrative purposes
because of its ample cytoplasm. A prominent filopodia
and lamellipodium formation associated with fascin1
localization was observed in control conditions and
EGF-treated cells, whereas these cytoskeleton structures
were absent in those cells treated with migrastatin or
imipramine to a similar extent to what was observed
with the migration inhibitor targeting the MEK pathway
(PD98059). The lamellipodia protrusion number was
calculated in HCT-116 cells in a quantitative manner
under the different conditions, and this number was
significantly lower after migrastatin and imipramine
treatments (Supplementary Information S2). Taken
together, these results identify an effect of imipramine in
diminishing invasive actin cytoskeleton structures and
fascin1 localization in such structures.
Imipramine diminishes the migration of colorectal cancer
cells
To explore whether the observed effect of fascin1
inhibitors on lamellipodium protrusion has a reflexive
effect on basal cell migration, migrastatin- and
imipramine-treated cells were investigated for their
migration activity within the linear growth phase (4−7 h
after in vitro scratch). As shown in Supplementary
Information S6, imipramine produces a remarkable
inhibition of migration in all assayed cell lines (p < 0.05).
Except for SW-480, the imipramine effect was more
pronounced than migrastatin, especially for DLD-1.
Table S3 shows the quantitative reduction in migration-
associated migrastatin and imipramine treatment in
DLD-1, SW-480, and HCT-116 colorectal cancer cell
lines (Supplementary Information S1). To correlate
fascin1 expression with a quantifiable effect on cell
migration, fascin1 expression was then silenced in HCT-
116 cells and overexpressed in DLD-1 cells (Supple-
mentary Information S1 and S7). Fascin1-silenced HCT-
116 cells led to a slight decrease in migration compared
with MOCK HCT-116 cells, while double inhibition
(epigenetic and pharmacological) produced a significant
decrease in migration. Transfected DLD-1 cells over-
expressing fascin1 showed a 15% higher migration
activity, which was counteracted in the presence of
10 µM imipramine.
Imipramine inhibits cell invasion through Matrigel
In addition to migration, tumoral cell invasion involves
the acquisition of the ability to degrade the extracellular
matrix (ECM). For this purpose, a transwell assay was
performed on Matrigel, which resembles the ECM com-
position. As shown in Supplementary Information S8,
both migrastatin and imipramine inhibited tumor cell
invasion of HCT-116 cells. Similar to the in vitro migra-
tion test, the effect of imipramine was slightly more evi-
dent than that of migrastatin. Importantly, the addition of
imipramine to fascin1 knockdown HCT-116 cells did not
decrease invasion further; however, it obviously amelio-
rated invasion caused by fascin1 overexpression in
transfected DLD-1 cells (Supplementary Information S7).
This inhibition clearly revealed a fascin1-dependent effect
on migration and invasion capacities.
Imipramine diminishes HCT-116 colon cancer cell invasion
in human benign leiomyoma tissue in an in vitro 3D model
To determine whether the anti-invasive properties of
imipramine could be translated into human tissue of
stromal origin, a myoma organotypic model was used to
Fig. 3 F-actin bundling activity assay. a Assay of actin-bundling
activity with a low-speed cosedimentation assay. Polymerized F-actin
(10 µM) was incubated with fascin1 (1 µM) in the presence (+) or
absence (−) of imipramine and DMSO (control). b Quantification of
the F-actin bundling assay from (a). The results are the means and SD
(n= 4, *p < 0.01).
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test the invasion of HCT-116 colorectal cancer cells. As
shown in Fig. 6, imipramine inhibited both the depth and
the area of invasion of HCT-116 cells compared with
control conditions and to a comparable extent as
migrastatin.
Imipramine inhibits the invasive and metastatic capacity of
colorectal tumor cells in an in vivo model
To undercover whether the anti-invasive properties of
imipramine could be extrapolated to an animal system,
the well-established zebrafish larvae invasion model was
Fig. 4 TEM visualization of actin binding and bundling activities in the presence of fascin1 and inhibitors (negative staining). a Stained
polymerized F-actin filaments alone. b Under control conditions (DMSO), actin filaments were incorporated into bundles in the presence of untreated
fascin1 at a 1:1 ratio. c Binding and bundling assays with filamentous F-actin and fascin1 previously incubated with 100 μMmigrastatin. d Binding and
bundling assays with filamentous F-actin and fascin1 previously incubated with 10 μM imipramine. High-magnification images (×93,000) show
examples of aberrant morphology in the treated fascin1 conditions (c, d). e Quantitative analysis of the numbers of actin filaments in the presence of
the compounds and comparison to control conditions (***p < 0.001).
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Fig. 5 Cell morphology of HCT-116 and HaCat cells upon inhibition of lamellipodia and filopodia formation. Inset shows the
immunofluorescence analysis of the fascin1 marker (green) under control conditions: a–f control conditions, b–g 10 ng/mL EGF (migration
stimulator), c–h 50 µM PD98059 (MEK inhibitor), d–i 100 µM migrastatin, and e–k 20 µM imipramine. Images were captured using an LSM 510 META
confocal fluorescence microscope with a ×63 oil objective. Scale bar 30 µm. Migrastatin and imipramine inhibit lamellipodia protrusion and fascin1
localization in a similar way to the migration MEK inhibitor PD98059 in both cell lines.
Fig. 6 Myoma organotypic invasion model showing. a The effect of 100 µM migrastatin and imipramine (10 and 20 µM) on the HCT-116
colorectal cell line. Quantifiable effect on the invasion area (b) and on the invasion depth (c). **p < 0.001, ***p < 0.0001.
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used, and a xenograft assay was performed (Fig. 7a). The
vast majority of larvae were viable when treated at all
concentrations; however, the combination of 20 µM
imipramine and the injection of naive HCT-116 or
transfected DLD-1 resulted in lethality for all larvae
after the second day post xenograft (Supplementary
Information S9). To check for a dose-dependent effect, 5
and 10 µM concentrations of imipramine were included
in the following experiments. The percentage of inva-
sion correlated with fascin1 mRNA expression; HCT-
116 had the highest expression, and LoVo and DLD-1
cells had the lowest fascin1 expression and invasion
percentage (Fig. 7a). For that reason, HCT-116 was
selected as the cell line with the highest constitutive
fascin1 expression, and fascin1-transfected DLD-1 cells
were selected as the condition to test the effect of
induced fascin1 expression. The fascin1-transfected
cells increased the level of protein expression and the
percentage of zebrafish larvae invasion (Fig. 7c).
Imipramine treatments of larvae exhibited a sig-
nificantly lower percentage of invasion and a lower
number of invasive HCT-116 cells than the control,
similar to that observed for migrastatin (Fig. 7b). Simi-
larly, E3 medium treated with imipramine and migrastatin
(treatment after cell injection) also diminished fascin1-
transfected DLD-1 cell invasion, and this effect was dose-
dependent for imipramine (Fig. 7d). The same inhibitory
effect was observed when tumor cells were treated prior
Fig. 7 Zebrafish invasion assays 4 days post xenograft. a The images show the invasive and noninvasive cells in a zebrafish invasion model. The
invasiveness of each cell line in this model is shown in the right panel. b HCT-116 cancer cells were treated with migrastatin and imipramine and
then injected into zebrafish larvae. The effect of imipramine in diminishing the cell invasion percentage and the number of invasive cells is similar to
that of migrastatin. c Fascin1 mRNA levels in transfected DLD-1 cells and cell invasion associated with transfection (lower panel). d Effect of drugs on
the average percentage of zebrafish larvae invasion in fascin1-transfected DLD-1 cells. Data are shown as the mean ± SD, compared with the control,
*p= 0.049–0.01; **p= 0.001–0.009; ***p= 0.0001–0.0009; ****p < 0.0001.
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to injection (Supplementary Information S10). When
larvae were fed and kept alive 6 days post xenograft,
micrometastasis developed from invading tumor cells. As
presented in Fig. 8, HCT-116 colorectal cancer cells were
treated with 5 and 10 µM imipramine, causing a sig-
nificant decrease in the number of larvae with metastasis
in a dose-dependent manner. When DLD-1 cells were
transfected with the fascin1-GFP vector, a significant
increase in larvae with metastasis was observed compared
with the pGFP-N3 control vector (MOCK). This meta-
static activity diminished when larvae were treated with
the lowest imipramine dose with anti-invasive activity
(Supplementary Information S11).
Discussion
Our prior study demonstrated, using expression profil-
ing, that fascin1 is overexpressed in SAC compared with
CC (88.6% vs. 11.6%)3. The high frequency of KRAS or
BRAF mutations confers SAC with an important resis-
tance to current anti-epidermal growth factor receptor
therapies9,10. Similarly, several authors have reported that
fascin1 is overexpressed in triple negative/basal pheno-
type breast carcinoma22–24. Given the role of fascin1 in
invasion and metastasis, we performed a bioinformatic
search for in silico identification of chemical compounds
blocking this protein.
We found that imipramine, a tricyclic antidepressant
(TCA), gave a high score in the bioinformatics analysis,
which was subsequently validated in vitro by Thermofluor,
fluorescence titration experiments, and TEM. The applica-
tion of imipramine in fascin1-overexpressing tumors is
patent pending by the authors (no. 18382696.5). A previous
study by Jahchan et al.25 demonstrated the antitumoral
effects of imipramine in human small cell lung cancer and
other neuroendocrine tumors implanted in mice. In a clinical
setting, Sauer and Lang reported unexpected survival asso-
ciated with imipramine treatment in a patient with metastatic
lung cancer26, and the epidemiological study by Walker
et al.27, which included 31,953 cancer cases from different
locations and 61,591 matched controls, concluded that tri-
cyclic antidepressants such as imipramine may have potential
for the prevention of both colorectal cancer and glioma in a
dose- and time-dependent fashion. The antidepressant
effects of TCAs are thought to be due to an overall increase
in serotonergic neurotransmission (https://www.drugbank.
ca/drugs/DB00458); however, despite the aforementioned
evidence, no clear molecular targets have been linked to the
antitumoral activity of imipramine. Compelling evidence
suggests that imipramine is able to cross the plasma mem-
brane and inhibit intracellular targets. Indeed, CACO-2, a
colorectal cancer cell line used to test drug intestinal
absorption, was found to be permeable to imipramine
(https://www.drugbank.ca/drugs/DB00458).
Furthermore, Kraft et al., by screening 1040 compounds
using cultured fascin1-deficient mutant Drosophila neu-
rons, whose neurite arbors manifest the “filigree” pheno-
type, identified imipramine as a fascin1 pathway blocker.
Moreover, these authors demonstrated that single sub-
stitutions found in other antidepressants (desipramine, tri-
mipramine, and clomipramine) suppress this anti-fascin1
pathway phenotype28. Nonetheless, none of these other
antidepressants received a significant score in our in silico
screening, thus suggesting a direct binding of imipramine to
fascin1 and not to other proteins of its pathway. The
functional enrichment analysis presented here is also sug-
gestive of an effect of imipramine on the actin cytoskeleton
because 3 out of 18 GO molecular functions associated with
imipramine treatment are cytoskeleton-related. Despite this
evidence, an additional off-target antitumoral effect of
imipramine beyond fascin1 is also possible.
The relationship between neural markers and fascin1
overexpression was further confirmed by the fact that
neuroblastoma cell lines have the highest fascin1 expres-
sion and that Munson et al.29 demonstrated that
Fig. 8 Antimetastatic potential of imipramine in zebrafish. a At day 6 post injection, larvae were examined to evaluate whether micrometastasis
developed by invading native HCT-116 cells. b The evaluation criteria were the presence of human cancer cell colonies (arrows) outside the yolk sac.
Invading single cells are indicated by asterisks (*). Data are shown as the mean ± SD, compared with the control, *p= 0.049–0.01; **p= 0.001–0.009.
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imipramine blue, an imipramine derivative, showed anti-
invasion properties against malignant glioma cells in vitro
and in vivo. As Kraft et al. pointed out, although the
design of the study by Munson et al. was based on the
inhibition of NADPH oxidase by imipramine blue, glioma
cells treated in vitro showed a dramatic reorganization of
their actin cytoskeleton, with marked loss of actin bundle-
based protrusions and extensions28,29, which is consistent
with our findings of a direct effect of imipramine causing
loss of fascin1 function28.
Of note, in our study, the HCT-116 colorectal cell line
was used for its highest fascin1 expression out of eight
CRC cell lines. However, we cannot assure that the pri-
mary tumor for this cell line could be an SAC, as this
information was not recorded when establishing tumor
cell lines, and there is no CRC cell line typified as from
SAC origin. Previous articles highlight that cancer cell
lines maintain their morphological features and meta-
static potential in zebrafish xenografts and further validate
the chemosensitive profile of HCT-116 cells in zebrafish
and mouse xenografts. The results in mouse xenografts
closely matched with zebrafish xenografts20,30. It is worth
noting that in our study, imipramine did not seem to be
toxic to zebrafish at anti-invasive doses.
This study reports, for the first time, an antimigratory
and anti-invasive effect of imipramine, an FDA-approved
antidepressant oral agent, in colorectal tumor cells pos-
sibly due to anti-fascin1 activity, thus paving the way for a
new molecular targeted treatment in SAC and other
fascin1-overexpressing tumors.
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